Tibolone: Tissue-Specific Clinical Effects

1. Lindsay R Hart DM Kraszewski A. Prospective double-blind trial of synthetic steroid (ORG OD14) for preventing postmenopausal osteoporosis. Br Med J 1980; 2: 1207–9

2. Funder JW Pearce PT Smith R Smith AI . Mineralocorticoid action: target tissue specificity enzyme, not receptor mediated. Science 1988; 242: 583–85

3. Markiewicz L Gurpide E. In-vitro evaluation of oestrogenic, oestrogen antagonist and progestogenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 1990; 35: 5525–41.

4. Tang B Markiewicz L Kloosterboer HJ . Human endometrial 3-β OH steroid dehydrogenase/isomerase can locally produce intrinsic oestrogenic/progestogenic activity ratios of a steroidal drug (ORG OD14). J Steroid Biochem Molec Biol 1993; 45: 345–51.

5. Johannes E. Tibolone: vaginal bleeding and the specific endometrial response in postmenopausal women. Gynecol Endrocrinol 1997; 2(S2): 25–30.

6. Hammar M Christau S Nathorst-Boos J. Rud T. Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904–11.

7. Crona N Samsioe G Lindberg UB Silfverstolpe G. A treatment of climacteric complaints with ORG OD14: a comparative study with oestradiol valerate and placebo. Maturitas 1988; 9: 303–8.

8. Egarter C Huber J Leikermoser R. Tibolone versus conjugated oestrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996; 23: 55–62.

9. Tax L Goorissen EM Kicovic PM . Clinical profile of ORG OD14. Maturitas 1987; S1; 3–13.

10. Nathorst-Boos J Hammar M. Effect on sexual life - a comparison between tibolone and a continuous oestradiol norethis-terone acetate regimen. Maturitas 1997; 26: 15–20.

11. Genazzani AR Petraglia F Facchinetti F . Effects of OD14 on pitutary and peripheral b-endorphin in castrated rats and postmenopausal women. Maturitas 1987; S1(35–48

12. Davis SR Berger HG . Androgens and the postmenopausal woman. J Clin Endocrinol Metab 1996; 81: 2759–63.

13. Kasson PR Elkind-Hirsch K Buster JE Hornsby PJ Carson SA . Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol 1997; 90: 995–98.

14. Michaëlsson K Baron JA Farahmand BY . Hormone replacement therapy and risk of hip fracture: population based case-control study. BMJ 1998; 316: 1858–63.

15. Berning B Kuijak CB Kuiper JW Coelingh-Bennink HJT Kicovic PM Fauser BCJM . Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two year randomised, placebo controlled study. Bone 1996; 19: 395–9.

16. Lippuner K Haenggi W Birkhauser MJ Jaeger P. Prevention of postmenopausal bone loss using tibolone, conventional peroral or transdermal replacement therapy. J Bone Miner Res 1997; 12: 806–12.

17. Prelevic GM Bartram C Wood J Okolo S Ginsburg J. Comparative effects on bone mineral density of tibolone, transdermal oestrogen and oral oestrogen/progestogen therapy in postmenopausal women. Gynecol Endocrinol 1996; 10: 413–20.

18. Studd J Amala I Kicovic P Zamblera D Kroger H Holland N. A randomised study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998; 92: 574–79.

19. Lindsay PC Shaw RW Coelingh-Bennink HJ Kicovic P. The effect of add-back treatment with tibolone (Livial) on patients treated with gonadotropin releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 1996; 65: 342–8.

20. Milner M Sinnot M Gasparo D Kelly A Carole BK Harrison R. Climacteric symptoms, gonadotropins, sex steroids and binding proteins with conjugated equine oestrogen/progesten and tibolone over two years. Menopause 1996; 3: 208–13.

21. Khosla S Milton J Atkinson E O'Fallon WM Klee GG Riggs BL . Relationship of serum sex steroid levels on bone turnover markers and bone mineral density in men and women: a key role for bioavailable oestrogen. J Clin Endoc Metab 1998; 83: 2266–73.

22. Haenggi W Linder HR Birkhauser MH Schneider H. Microscopic findings of nailfold capillaries - dependence on menopausal status and hormone replacement therapy. Maturitas 1995; 22: 37–46.

23. Lloyd GWL Patel NR McGing EA Cooper AF Kamalvand K Jackson G. Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina. IJCP 1998; 52: 155–57.

24. Cagnacci A Mallus E Tuveri F Cirillo R Setteneri AM Melis GB . Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997; 82: 251–3.

25. Rymer J Crook D Sidhu M . Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993; 128: 25–62.

26. Bjarnason NH Bjarnason K Haarbo J Coelingh-Bennink HJ Christenson C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997; 82: 175–6

27. Rosati D Micheli S Pinto S . Changes in lipidic and haemostatic parameters induced by tibolone treatment. Thromb Res 1997; 85: 273–8.

28. Erel CT Elter K Akman C . Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998; 69: 870–75.

29. Valdivia I Ortega D. One year evaluation of mammary radiographic density changes with different HRT regimens in climacteric women. Acta Obstet Gynaecol Scand 1997; 76(S176)(Abstract P 48.8).

30. Moore RA . Livial: a review of clinical studies. Br J Obstet Gynaecol 1999; 106(suppl 19): 1–21